Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Wolverine Trading LLC

Wolverine Trading LLC grew its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 131.5% during the third quarter, Holdings Channel reports. The firm owned 19,677 shares of the company’s stock after purchasing an additional 11,177 shares during the period. Wolverine Trading LLC’s holdings in Progyny were worth $331,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PGNY. SG Americas Securities LLC acquired a new stake in shares of Progyny during the second quarter worth about $374,000. Envestnet Portfolio Solutions Inc. increased its position in Progyny by 141.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 20,393 shares of the company’s stock worth $583,000 after buying an additional 11,934 shares during the period. 1620 Investment Advisors Inc. purchased a new stake in Progyny in the second quarter valued at approximately $97,000. Bank of New York Mellon Corp boosted its holdings in shares of Progyny by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company’s stock valued at $21,636,000 after acquiring an additional 22,012 shares during the period. Finally, RiverPark Advisors LLC grew its position in shares of Progyny by 9.6% during the second quarter. RiverPark Advisors LLC now owns 5,408 shares of the company’s stock worth $155,000 after acquiring an additional 474 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Down 1.7 %

Shares of PGNY stock opened at $14.61 on Friday. The stock has a market cap of $1.24 billion, a P/E ratio of 25.19, a P/E/G ratio of 1.73 and a beta of 1.35. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08. The business has a fifty day simple moving average of $15.53 and a 200-day simple moving average of $21.34.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the prior year, the company earned $0.16 earnings per share. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Progyny, Inc. will post 0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Jefferies Financial Group reduced their price target on shares of Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, September 19th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $17.00 target price (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Bank of America dropped their price target on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Truist Financial reaffirmed a “hold” rating and set a $19.00 price objective (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, JMP Securities lowered Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $25.00.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.